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A B S T R A C T
Background and purpose: This systematic review and meta-analysis aimed to assess the effects of vitamin D
supplements on indices of glycemic control [homeostatic model assessment-insulin resistance (HOMA-IR), he-
moglobin A1C (HbA1C), fasting blood glucose (FBG), and quantitative insulin-sensitivity check index (QUICKI)
and lipid profile in diabetic patients.
Methods: Eight databases were searched, for randomized controlled trials (RCTs) or cross-sectional and cohort
studies that have been published up to December 2017. We used the comprehensive meta-analysis (CMA)
software for all statistical analysis and used the I2 index for assessing heterogeneity. A p value of< 0.05 was
considered as statistically significant.
Results: We found 621 articles, and after the exclusion of ineligible publications, 82 studies remained to be
assessed of which 37 were used for meta-analysis. Vitamin D supplementation was associated with a significant
improvement in FBG (p= 0.001 and 95% CI: −0.526 to −0.136) and HbA1C (p= 0.003 and 95% CI: 1.719 to
−0.361) in individuals with type 2 diabetes mellitus (T2DM); while in women with gestational diabetes mellitus
(GDM) the reduction in FBG (p= 0.071 and 95% CI: −0.873 to −0.035) and HbA1C (p= 0.199 and 95% CI:
3.270 to 0.681) failed to reach statistical significance. Treatment with vitamin D supplements was associated
with an improvement in HOMA-IR in pregnant diabetic women (p= 0.028 and 95% CI: 0.924 to −0.053) and
for individuals with diabetes mellitus (p=0.005 and 95% CI: 1.772 to −0.319). The pooled result of the cross-
sectional meta-analysis indicated that serum vitamin D concentrations were significantly lower in diabetic pa-
tients than in healthy controls (p=0.018 and 95% CI: 0.587 to −0.054).
Conclusion: This meta-analysis suggests that vitamin D supplementation improves indices of glycemic control
(FBG, HOMA-IR, and HbA1C) in patients with diabetes mellitus. Hence, vitamin D supplements may be of
potential therapeutic value in diabetic patients, as an adjuvant therapy along with other treatments.
1. Introduction
Diabetes mellitus, is one of the most common chronic metabolic
disorders and a significant global health concern [1]. Diabetes is
characterized by hyperglycemia caused by insufficient secretion of in-
sulin, insulin resistance, or both [2]. Deleterious long-term effects of
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diabetes include macro- and micro-vascular disease, neuropathy, and
nephropathy [3]. Furthermore, there is a relationship between diabetes
and an increased risk of some cancers, that include: pancreatic, breast
and colorectal cancers [4,5]. The International Diabetes Federation
(IDF) has estimated that the number of people with diabetes is 425
million globally, of whom two-thirds live in industrial areas [6]. More
than 60% of diabetic patients globally are located in Asia [7]. Ap-
proximately 4.5 million adult diabetic patients live in Iran and it is
estimated 9.2 million people will be diabetic by 2030 [8]. There are
three main categories of diabetes mellitus [2]:
• Type 1 diabetes mellitus (T1DM): T1DM or Insulin dependent dia-
betes mellitus (IDDM) is an autoimmune disease, in which pan-
creatic beta cells are targeted for destruction by T-cells [9], and in
which genetic and environmental factors have an important role
[10].• Type2 diabetes mellitus (T2DM): T2DM is known as "non-insulin-
dependent- diabetes mellitus" (NIDDM). This is the most common
form of diabetes mellitus, and is associated with insulin resistance
[11].• Gestational diabetes mellitus (GDM): GDM is glucose intolerance,
often associated with hyperlipidemia and insulin resistance [12,13]
that arises in the second or third trimester of pregnancy, and can
affect women without a past history of impaired glucose tolerance,
and has a negative impact on fetal and neonatal well-being [11,14].
Vitamin D is a pro-hormone [15] that has an important role in in-
sulin secretion [16], although its classical role is in the regulation of
intestinal absorption of calcium, phosphate and their homeostasis [17].
Its sources include dermal synthesis following exposure to sunlight,
from the diet (salmon, mackerel) and dietary fortification and supple-
ments [18,19]. Vitamin D deficiency and insufficiency is now becoming
a global health concern and affects over one billion children and adults
[20,21]. Some studies have shown a high prevalence of vitamin D de-
ficiency in tropical and sub-tropical countries that include: Iran,
Turkey, China, India and, Saudi Arabia [22]. In Iran, approximately
(3.9–6.6 million) people are affected with DM [6]. Vitamin D deficiency
is associated with hypertension [23], cardiovascular disease [24], glu-
cose intolerance, insulin resistance and increased risk of diabetes [25].
A serum 25-hydroxyvitamin D [25(OH)D] level of< 20 ng/ml is asso-
ciated with increased risk of colon, prostate, and breast cancer [26,27].
There appears to be an inverse relationship between the risk of DM, its
complications and, serum 25(OH) D levels [28,29]. Therefore, DM is
more common in vitamin D deficient subjects and vitamin D may also
have beneficial anti-inflammatory effects [31]. There have been trials
of vitamin D supplementation in individuals with DM [30,31] although
there has been no comprehensive evaluation of the association between
vitamin D and DM. Therefore, we aimed to conduct this systematic and
meta-analysis by pooling the results from clinical trials and cross-sec-
tional studies to investigate the potential relationship between vitamin
D and DM.
2. Method
2.1. Search of literature
Relevant articles were identified using PubMed, Scopus, Web of
Science, Cochrane Library, Google Scholar, ScienceDirect, Scientific
Information Database (SID) and IranMedex up to December 2017. The
search terms used were the following combination of keywords: (“vi-
tamin D” or Vit D “25(OH)D”) AND (diabetes or DM or diabetic) AND
Iran) [MeSH Terms] OR (“vitamin D” or “25(OH)D”) AND (diabetes or
DM or diabetic) AND Iran) [All Fields], and Persian keywords in the
title, abstract, and keywords. Initially, we evaluated all original articles
in both English and Persian language including cross-sectional studies,
cohort and randomized controlled trials that assessed the correlation
and effect of vitamin D with or on DM, with no limitation for date. In
the case of RCTs, we included all clinical trials with vitamin D (in forms
of supplement or enriched in food) as the intervention and calcium, or
placebo, as a control. The outcomes of interest in these studies were:
fasting blood glucose (FBG), HbA1C and homeostatic model assess-
ment-insulin resistance (HOMA-IR). Cell-line, animal experiments, re-
view articles, laboratory studies, irrelevant topics, duplicate publica-
tion, non-clinical trials, and case reports were excluded. Other
exclusion criteria included: incomplete data sets, the difference in
baseline characteristics of all outcomes of interest, or lacking data
about their similarity at baseline (in RCTs), book chapters, an absence
of relevant data, lack of accurate data needed for our analysis. The
quality appraisal for each article was performed according to particular
criteria outlined by Joanna Briggs for cross-sectional studies and RCTs
[32]. Studies with high scores (> 50%) were considered to be high
quality.
2.2. Data extraction
Data extracted included: the last name of the first author and pub-
lication year, location and type of study, sample size with the drop-out
rate of population if available, population characteristics (number, age,
sex), serum vitamin D concentration, dose, and duration of intervention
25(OH)D, assessment of further outcomes and limitation of the study
were noted. In some studies, for which relevant data were missing,
contact was made with the principal authors for more information. All
the articles included were independently assessed by two reviewers
(MR and RS) who read the full-text of the papers, and a consensus was
reached in case of any inconsistency with the involvement of a third
author (M. E).
2.3. Statistical analysis
Comprehensive meta-analysis (CMA) software was used for all sta-
tistical analysis. The I2 index was used to assess heterogeneity, and in
case of heterogeneity (I2 value > 50%). A P < 0.05 was considered
statistically significant.
2.4. Search results and study characteristics
Fig. 1 shows the study selection data. We identified 621 articles
using a systematic search, of which 53 studies were excluded because of
duplication. From the remaining 568 studies, 463 publications were
excluded because they were review articles, laboratory studies, irrele-
vant topics, duplicate publication, or non-clinical studies. The re-
maining 105 papers were evaluated for eligibility by examining their
full text and 23 studies excluded because of incomplete data, or because
they were book chapters, or animal studies. Finally, 82 articles re-
mained to be assessed. There were 52 RCTs, 29 cross-sectional and one
cohort study. These 82 studies were analyzed based on the quality
measurement scale and inclusion and exclusion criteria. Although 82
studies were found to be appropriate for systematic analysis, 45 studies
were excluded because the groups were not matched and differed sig-
nificantly for glycemic indices at baseline. Some studies investigated
gene polymorphisms, and did not document glycemic indices. A total of
37 articles were used for meta-analysis. In all, 11614 and 1673 in-
dividuals were included in the systematic review and meta-analysis,
respectively.
2.4.1. The relation between serum vitamin D and measures of diabetes
mellitus
Table 1 shows the results of RCTs on the effects of vitamin D sup-
plementation or vitamin D fortified food versus placebo, calcium or
non-fortified food. The data indicate that vitamin D supplementation
significantly reduced HOMA-IR, HbA1C, fasting blood glucose (FBG),
and high-sensitivity C-Reactive Protein (hs-CRP). Vitamin D
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supplementation was associated with an improvement in lipid profile
and insulin sensitivity by Quantitative Insulin-Sensitivity Check Index.
The data for the cross-sectional and cohort studies are shown in Table 2.
Unsurprisingly, FBG, HbA1C, and HOMA-IR were higher in the diabetic
patient compared to healthy subjects, and serum vitamin D was lower
in diabetics than in healthy controls.
3. Results
Fig. 3 shows the results of the meta-analysis for RCTs for FBG. The
overall pooled results for the effects of vitamin D supplementation on
FBG in GDM were not significant (p= 0.071, and 95% CI: −0.873 to
0.035) for GDM, but were significant in T2DM (p= 0.001, and 95% CI:
−0.526 to −0.136). Although the relative weight of the study of Va-
lizadeh et al. on GDM patients was higher than other studies, the result
of this study was also non-significant (p=0.119). Furthermore, the
results of the sensitivity analysis showed that following the elimination
of the study of Valizadeh et al. the final results were significant. Perhaps
the high-dose vitamin D consumption and short-term follow up in Va-
lizadeh's study in comparison with other studies may have been the
cause of the lack of a significant result. Overall, vitamin D supple-
mentation was associated with a significant improvement in FBG in
diabetic patients (Fig. 3a and b).
Fig. 4 shows that vitamin D supplements had no significant effect on
HbA1C in GDM (p=0.199 and 95% CI: 3.270 to 0.681), but there was
a significant effect on HbA1C in T2DM (p= 0.003 and 95% CI: 1.719 to
−0.361). However, only the intervention study of Yazdchi in pregnant
diabetic patients revealed significant effects, which may be due to
factors such as the assessment of dietary intakes, use of matched cate-
gories regarding known confounders, sunlight exposure and pre-preg-
nancy BMI. Overall the final result was significantly in favor of inter-
vention. This means that the intervention leads to a significant
reduction in HbA1C in T2DM.
In Fig. 5, the study by Yazdchi et al. reported that vitamin D was not
associated with an improvement in HOMA-IR, but overall, after in-
creasing vitamin D intake, this did improve significantly (p= 0.028
and 95% CI: 0.924 to −0.053) in pregnant diabetic women. Also, vi-
tamin D supplements were associated with a significant improvement in
HOMA-IR (p=0.005 and 95% CI: 1.772 to −0.319) in DM patients
(Tables S1–S6).
In Fig. 6 the overall pooled result of cross-sectional meta-analysis
indicated vitamin D level was lower (p=0.018 and 95% CI: 0.587 to
−0.054) in diabetic patients than for healthy controls (Table S7).
4. Discussion
We have undertaken a systematic review of the effects of dietary
vitamin D on lipid profile, glycemic control and insulin resistance index
in diabetic patients, that included GDM, T1DM, and T2DM. GDM affects
approximately 4.7% of pregnant women in Iran [106]. Various factors,
such as vitamin D deficiency and fast food intake are suggested as a risk
factor for GDM [107,108]. In our systematic review, we found that
Fig. 1. Flow chart of literature search and study selection.
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fasting plasma glucose (FPG) [80,83], HbA1C [81] and HOMA-IR were
significantly higher in women with GDM, whereas serum insulin [81]
and vitamin D levels [80] were lower compared with healthy control.
Furthermore, vitamin D supplementation was associated with a sig-
nificant reduction in HOMA-IR [36], FPG [44] and insulin [36] and an
increase in QUICKI and sensitivity to insulin in the intervention group
[40]. In agreement with previous studies, Shahgheibi et al. demon-
strated, vitamin D supplementation intake has potentially beneficial
effects as assessed by an improvement in glucose tolerance test (GTT)
and reduction in the prevalence of GDM [39]. In a cohort study in
Tehran, GDM subjects with postpartum metabolic syndrome had higher
fasting glucose, and lower serum parathyroid hormone (PTH) than
healthy control [84]. In some studies, vitamin D supplementation did
not affect FPG [43], or insulin resistance [43] and there was no sig-
nificant relationship between GDM with serum vitamin D levels
[80,83]. Overall vitamin D consumption in women with GDM improved
measures of glycemic status [36] and HbA1C levels and no complica-
tions have been reported [44]. Vitamin D plays a potentially important
role in T1DM by suppressing activation of T-cells [97]. Although
Ghandchi and co-workers report that FSG and HbA1C were higher in
patients with T1DM compared to healthy control, serum vitamin D did
not differ significantly between the subjects and unrelated non-diabetic
controls. It has been proposed that vitamin D consumption in those who
are genetically predisposed to the disease (i.e., siblings) may prevent
T1DM [99]. Consumption of vitamin D supplements have a beneficial
effect on HbA1C [48] and FBG in patients with T1DM and vitamin D
insufficiency [46]. Ataie-Jafari et al. found that children with T1DM
who are exposed to sunlight ≥15min at weekends have a lower pre-
valence of vitamin D deficiency than T1DM children with< 15min
exposure to sunlight. Because exposure to sunlight is an important
source of vitamin D and also according to Ghandchi et al., vitamin D
levels are important to the T helper 1 and T helper 2 balance and
susceptibility to T1DM [47]. Saki at al observed the prevalence of vi-
tamin D deficiency in boys with T1DM was lower than for girls [85].
Finally, we suggest that vitamin D supplementation could be an aux-
iliary treatment in patients with T1DM. According to the 8th Interna-
tional Diabetes Federation (IDF), the prevalence of T2DM in Iran is in
excess of 4 million (8.43%) [109]. A low serum 25-hydroxy vitamin D
[25(OH)D] has been associated with impaired glucose tolerance in
T2DM [52]. The concentration of serum vitamin D is reported to be
lower in diabetic patients than in healthy people [23,87,90,104,105].
Esteghamati et al. showed that vitamin D deficiency is associated with
reduced insulin-producing in T2DM [101]. RCTs indicate that vitamin
D supplements can improve serum vitamin D level [55], glycemic in-
dicator [49,53,55,65,78], serum hs-CRP [53,68,69], lipid profile and
HOMA-IR [49,55,60,72]. Furthermore, several studies have shown that
HbA1C is reduced in intervention group compared to control group
[53,60,64,72,110,111]. However, in some studies HbA1C was reduced
in both groups. It is possible that the improvement in the control group
was due to dietary change and taking plain doogh that contains calcium
without vitamin D [61,112,113]. In contrast to these studies, Eftekhari
and Jafari showed that HbA1C was increased in the intervention and
control group [114,115] and in similarly Ahmadi et al. indicated
HbA1C is increased in intervention group only. Moreover vitamin D
supplementation for three months had no significant effect on reducing
proteinuria in diabetic patients [70]. Some studies have demonstrated
that dietary vitamin D intake reduces insulin in the intervention group
[51,60,68,72,111,115–117]. Furthermore, Heshmat demonstrated the
Fig. 2. The reported effects of vitamin D supplement in diabetics.
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Table 1
RCTs for the effects of vitamin D supplementation or vitamin D fortified food versus placebo, calcium or non-fortified food [25,31,33–79].
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*The mean concentration of vitamin D (before and after intervention) is shown in the study for each city; GDM: gestational diabetes mellitus; HbA1C: hemoglobin
A1C; T1DM: Type 1 diabetes mellitus; HOMA- β: Homeostatic Model Assessment β-cell function; T2DM: Type 2 diabetes mellitus; FPG: fasting plasma glucose;
HOMA-IR: Homeostatic Model Assessment Insulin Resistance; LDL: low-density lipoprotein; Ca: Calcium; Cr: Chromium; TC: total cholesterol; TAG: triacylglyceride;
FBG: fasting blood glucose; hs-CRP: high-sensitivity C-Reactive Protein; GCT: Glucose Challenge Test; GTT: Glucose Tolerance Test; 1-h OGTT: 1 h oral glucose
tolerance test; PTH: Parathyroid Hormone; QUICKI: Quantitative Insulin-Sensitivity Check Index; MMP-9: matrix metalloproteinase 9; FSG: fasting serum glucose;
TNF-α: tumor necrosis factor alpha; MDA: Malondialdehyde; SOD: superoxide dismutase; GSH: Glutathione; APO: Apolipoprotein; IL: Interleukin; HDL: High-Density
Lipoprotein; GFR: glomerular filtration rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; BUN: blood urea nitrogen; P: phosphate; UACR: urine
albumin/creatinine ratio; ↑: Increased level; ↓ decreased level.
Table 2
The cross-sectional and Cohort studies for the effects of vitamin D supplementation or vitamin D fortified food versus placebo, calcium or non-fortified food
[23,80–105].
GDM: gestational diabetes mellitus; T1DM: Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus; FPG: fasting plasma glucose; DBP: diastolic blood pressure;
HbA1C: hemoglobin A1C; HOMA-IR: Homeostatic Model Assessment Insulin Resistance; Ca: Calcium; hs-CRP: high-sensitivity C-Reactive Protein; LDL: Low-Density
Lipoprotein; GTT: Glucose Tolerance Test; FBG: Fasting blood glucose; PTH: parathyroid hormone; FSG: fasting serum glucose; TNF-α: Tumor Necrosis Factor-alpha;
VDR: vitamin D receptor; APO: apolipoprotein; SBP: systolic blood pressure; P: phosphate; PPG: post prandial glucose; HOMA- β: Homeostatic Model Assessment β-
cell function; BMI: body mass index; GFR: glomerular filtration rate; HC: Healthy control; ↑: Increased level; ↓ decreased level.
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consumption of vitamin D plus calcium is more effective compared with
intake vitamin D only to decrease the risk of T2DM [51]. Following
some previous studies, Mohammadi showed that vitamin D supple-
mentation leads to a significant reduction to insulin resistance in the
intervention group [76]. In some studies, calcium plus vitamin D sup-
plements have been shown to have a positive effect on BMI, hip cir-
cumference and systolic blood pressure in subjects with T2DM [71,72].
Hoseini et al. observed that the intake of vitamin D supplements did not
Fig. 3. Forest plots of the association between intake of vitamin D and FBG in RCTs (a) GDM and (b) T2DM studies. The centre of each square indicates the horizontal
line indicates the 95% CI; the area of the square is proportional to the amount of information from that study; diamonds are pooled estimates.
Fig. 4. Forest plots of the association between intake of vitamin D and HbA1C in RCTs (a) GDM and (b) T2DM diabetes studies.
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effect on insulin sensitivity, however it caused a reduction in FPG and
HbA1C, that was increased in pre-diabetic subjects [118].
4.1. Vitamin D fortification studies
The main source of vitamin D in humans is from synthesis in the
skin. Factors such as the duration of exposure, latitude, season, senes-
cence, skin pigmentation and the continued use of sunscreens can affect
the synthesis of vitamin D [119]. Although fortification of foods with
vitamin D is not usual in Iran, some research has led to the proposal that
the daily intake of a vitamin D should be increased by fortified yogurt
drink, either with or without added calcium, improved glycemic status
in T2DM patients [31,52,120]. Nikooyeh and Shab-bidar showed,
serum glucose, HbA1C, HOMA–IR, oxidative stress (OS) [85,86] and
insulin improved after vitamin D–fortified yogurt drink and vitamin D
plus calcium–fortified yogurt drink intaking in the intervention group
[52]. Furthermore, Hajmohammadi et al. have suggested vitamin D3-
fortified doogh compared with plain doogh leads to a reduction in
serum hs-CRP and parathyroid hormone (PTH) concentrations [58].
4.2. Vitamin D and diabetic neuropathy
Diabetic neuropathy (DN) is the most common complication of DM
and also a major cause of morbidity and mortality in diabetic patients.
Alamdari et al. in a cross-sectional study, observed reduction the levels
of circulating 25(OH)-D was associated with an increased risk of large
fiber neuropathy and FBG in type2 diabetic people [121]. In other re-
search, Esteghamati et al. suggested an intake of vitamin D should be
done more carefully, particular in diabetic subjects. As well as results
showed FPG and HbA1C were increased in DN [122].
4.3. Vitamin D & diabetic foot ulcer
Diabetic foot ulcer (DFU) is known as one serious vascular
Fig. 5. Forest plots of the association between intake of vitamin D and HOMA-IR in RCTs (a) GDM and (b) DM diabetes studies.
Fig. 6. Forest plot of the comparison between vitamin D level in Diabetic patients and Healthy control.
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complications of diabetes. Razzaghi indicated, in diabetic patients with
foot ulcer, vitamin D supplementation intake caused to improve glucose
homeostasis, lipid profiles, decreases HbA1C and FPG. They suggested,
improve glucose homeostasis had indirectly beneficial effects on wound
healing [123]. Pooled data from all studies suggested, intake vitamin D
supplement and vitamin D3-fortified doogh/yogurt improve several
factors in diabetic patients after intervention. In Fig. 2, some of the
effects of vitamin D on diabetics have been shown.
4.4. Strengths and limitations
This review is the first meta-analysis assessing the effect of vitamin
D on glycemic indices in diverse subgroups of diabetes and also, sum-
marizes cross-sectional, cohort and interventional studies in diabetic
patients. However, it should be noted that a major limitation of our
study is the lack of pre and post-baseline measures for glycaemic indices
in several papers, requiring them to be excluded from the meta-ana-
lysis.
5. Conclusion
This systematic and meta-analysis review demonstrated that vi-
tamin D had major effects on FBG of type 2 diabetics and pregnant
women with diabetes. Therefore, vitamin D could be used as an ad-
juvant therapy along with the other treatments for those patients. Also,
vitamin D supplementation leads to an improvement in HOMA-IR, FBG,
and HbA1C. Furthermore, the overall pooled result of the cross-sec-
tional meta-analysis showed the level of vitamin D is lower in diabetic
patients than healthy control significantly. However, further studies are
required to better understand the relationship between vitamin D
supplementation and glucose homeostasis indexes in type 2 diabetes
patients and pregnant diabetic women.
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